Beneficial Ownership Report · SCHEDULE 13G/A
Climb Bio, Inc.
CLYMNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Climb Bio, Inc.
- Company CIK
- 0001768446
- Street
- 20 William Street, Suite 145
- City
- Wellesley Hills
- State / country code
- MA
- Postal code
- 02481
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.0001 per share
- Event date
- 06/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- MPM BioImpact LLC
- Citizenship / organization
- DE
- Reporting person type
- IA
- Aggregate amount owned
- 0.00
- Percent of class
- 0.0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
Item 1
Issuer
Climb Bio, Inc.
Principal executive office address
20 William Street, Suite 145, Wellesley Hills, MA, 02481.
Item 2
Citizenship
Delaware
Filing person
MPM BioImpact LLC
Principal business or residence address
399 Boylston Street, Suite 1100 Boston, MA 02116
Item 3
Not applicable indication
N
Type of filing person
IA
Item 4
Percent of class
0.0%
Amount beneficially owned
0
Sole voting power
0
Shared voting power
0
Sole dispositive power
0
Shared dispositive power
0
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- MPM BioImpact LLC
- Signed
- Christopher Wolf
- Title
- Chief Financial Officer
- Date
- 08/14/2026
Company context
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.